Despite these findings, the lack of a specific small molecule drug targeting ACTN1 represents a significant challenge and highlights the urgency for the development of novel therapeutics aimed at depleting ACTN1 in HNSCC cells. Here, ACTN1 is linked to head and neck squamous cell carcinoma.